SSG
SRNE

Summit Securities Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Summit Securities Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-115
Closed -$111K – 930
2021
Q2 		$111K Buy
+115
New +$916 0.01% 675

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Summit Securities Group's SRNE Position: Q4 2022 in Review

Summit Securities Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 1,704 shares — an estimated $3K sold.

Summit Securities Group first reported a position in SRNE in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

  • Summit Securities Group reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Summit Securities Group sold 1,704 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $3K.
  • Summit Securities Group first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 1 quarter.
  • Summit Securities Group's Sorrento Therapeutics, Inc. position peaked at $3K in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Summit Securities Group's 13F filing for Q4 2022, filed 13 Feb 2023.